Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecelra
afamitresgene autoleucel · Adaptimmune
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic synovial sarcoma after chemotherapy, with HLA-A*02:01P, 02:02P, 02:03P or 02:06P and tumor MAGE-A4 expression on authorized companion tests.
LAMPGEN ANALYSIS
Why it matters
This engineered T-cell receptor therapy made cellular treatment available for a biomarker-defined subset of synovial sarcoma.
What research teams should watch
Align HLA typing, MAGE-A4 testing, leukapheresis and product delivery; each can affect whether the treatment window is feasible.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
HLA- and antigen-selected synovial sarcomaPRIMARY RECORDS